Interdisciplinary Research from F1000

These papers were selected from multiple disciplines from the Faculty of 1000, a Web-based literature awareness tool http://www.facultyof1000.com.L.T. Vassilev et al., "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2," Science, 303:844–8, Feb. 6, 2004.This paper is important because it challenges the conventional wisdom that protein-protein interactions are poor drug targets. p53 ... is inhibited when bound by MDM2. ... It is possible to disrupt the p53-MDM2 int

The Scientist Staff
May 9, 2004
<p></p>

These papers were selected from multiple disciplines from the Faculty of 1000, a Web-based literature awareness tool http://www.facultyof1000.com.

L.T. Vassilev et al., "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2," Science, 303:844–8, Feb. 6, 2004.

This paper is important because it challenges the conventional wisdom that protein-protein interactions are poor drug targets. p53 ... is inhibited when bound by MDM2. ... It is possible to disrupt the p53-MDM2 interaction in cells with a small organic molecule at low micromolar concentrations.

- William Kaelin, Harvard Medical School

W.C. Winkler et al., "Control of gene expression by a natural metabolite-responsive ribozyme," Nature, 428:281–6, March 18, 2004.

The authors report that glucosamine-6-phosphate (GlcN6P) activates a ribozyme embedded within the 5' untranslated region of the gene encoding its synthesis. This ribozyme cleaves the messenger RNA, thereby suppressing GlcN6P production. ... It will be interesting to see if...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?